New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
An emerging nomogram model for intra-tumoral heterogeneity quantification with breast MRI demonstrated an average 85 percent sensitivity in external validation testing for predicting pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
A systematic review of 147 clinical trials assessing neoadjuvant systemic therapy for breast cancer also revealed that mid-treatment imaging was utilized in 56 percent of the studies.